301196-85-0

Basic information

• Product Name: 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid
• Synonyms: 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid
• CAS NO: 301196-85-0
• Molecular Weight: 335.28
• Mol File: 301196-85-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid(301196-85-0)
• EPA Substance Registry System: 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid(301196-85-0)

Safety Data

• Hazardous Substances Data: 301196-85-0(Hazardous Substances Data)

Usage

Amino acid derivative

It is a derivative of an amino acid This compound is based on an amino acid structure, with modifications to its side chain or functional groups, which can alter its properties and potential applications.

Tert-butoxycarbonyl (Boc) protecting group

The presence of a Boc group in the compound This protecting group is commonly used in organic synthesis to temporarily protect an amine group in a molecule, allowing for further reactions to be carried out without affecting the amine group.

Trifluoromethoxy group

Contains a CF3OCH2group The presence of this electron-withdrawing group can influence the reactivity and properties of the compound, such as its solubility, stability, and potential biological activity.

Phenylacetic acid moiety

It contains a phenylacetic acid part This functional group is a key structural element in the compound, which can contribute to its chemical reactivity and potential applications in medicinal chemistry.

Potential applications in medicinal chemistry

The compound has possible uses in the field of medicinal chemistry This suggests that it could be further developed or modified to create new drugs or therapeutic agents.

Synthesis of complex organic compounds

The compound can be used as a building block or intermediate in the synthesis of other complex organic compounds This highlights its utility in organic synthesis and the potential for creating new molecules with various applications.

Dependence on further characterization and study

The specific properties and potential uses of this compound would depend on its further characterization and study This emphasizes the need for additional research to fully understand and exploit the properties and applications of 2-((tert-butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid.

Upstream product

• 950651-11-3 2-amino-2-(4-(trifluoromethoxy)phenyl)acetamide 
• 954582-33-3 amino(4-(trifluoromethoxy)phenyl)acetonitrile 
• 659-28-9 p-trifluoromethoxybenzaldehyde 

Relevant articles and documents

Discovery of a novel series of pyrazolo[1,5-a]pyrimidine-based phosphodiesterase 2A inhibitors structurally different from N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the treatment of cognitive disorders

It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in neuropsychiatric and neurodegenerative disorders through augmentation of cyclic nucleotide signaling pathways in brain regions associated with learning and memory. Following our earlier work, this article describes a drug design strategy for a new series of lead compounds structurally distinct from our clinical candidate 2 (TAK-915), and subsequent medicinal chemistry efforts to optimize potency, selectivity over other PDE families, and other preclinical properties including in vitro phototoxicity and in vivo rat plasma clearance. These efforts resulted in the discovery of N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20), which robustly increased 3′,5′-cyclic guanosine monophosphate (cGMP) levels in the rat brain following an oral dose, and moreover, attenuated MK-801-induced episodic memory deficits in a passive avoidance task in rats. These data provide further support to the potential therapeutic utility of PDE2A inhibitors in enhancing cognitive performance.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.